FrancophonIA/ELRC3.0 huggingface dataset:
English: The CHMP concluded that, in accordance with EU requirements, Docetaxel Mylan has been shown to be comparable to Taxotere.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Docetaxel Mylani võrreldavus ravimiga Taxotere.
English: This is a summary of the European public assessment report (EPAR) for Docetaxel Mylan.
Estonian: See on ravimi Docetaxel Mylan Euroopa avaliku hindamisaruande kokkuvõte.
English: No additional studies were needed as Docetaxel Mylan is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Taxotere.
Estonian: Lisauuringuid ei olnud vaja, sest Docetaxel Mylan on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Taxotere.
English: Because Docetaxel Mylan is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Docetaxel Mylan on geneeriline ravim, peetakse ravimi kasulikkust ja riske samadeks mis võrdlusravimil.
English: The Committee recommended that Docetaxel Mylan be given marketing authorisation.
Estonian: Komitee soovitas anda Docetaxel Mylani müügiloa.
English: Other information about Docetaxel Mylan
Estonian: Muu teave Docetaxel Mylani kohta
English: Docetaxel Mylan is used to treat the following types of cancer:
Estonian: Docetaxel Mylanit kasutatakse järgmiste vähivormide ravimiseks:
English: Docetaxel Mylan is used with prednisone or prednisolone (anti-inflammatory medicines);
Estonian: Docetaxel Mylanit kasutatakse koos prednisooni või prednisolooniga (põletikuravimid);
English: Docetaxel Mylan is used with cisplatin and 5-fluorouracil.
Estonian: Docetaxel Mylanit kasutatakse koos tsisplatiini või 5-fluorouratsiiliga.
English: This means that Docetaxel Mylan is similar to a ‘reference medicine' already authorised in the European Union (EU) called Taxotere.
Estonian: See tähendab, et Docetaxel Mylan on sarnane võrdlusravimiga Taxotere, millel juba on Euroopa Liidus müügiluba.
English: The company also showed that the Docetaxel Mylan solution for infusion has comparable quality to that of Taxotere.
Estonian: Ettevõte esitas ka andmed, et Docetaxel Mylani infusioonilahuse kvaliteet on võrreldav Taxotere kvaliteediga.
English: Docetaxel Mylan can be used on its own after other treatments have failed.
Estonian: Docetaxel Mylanit tohib kasutada ainsa ravimina pärast muude raviskeemide ebaõnnestumist.
English: It can also be used with cisplatin (another anticancer medicine) in patients who have not yet received any treatment for their cancer;
Estonian: Seda tohib kasutada ka koos tsisplatiiniga (samuti vähiravim) patsientidel, kes ei ole veel vähiravi saanud;
English: Docetaxel Mylan is used with cisplatin and 5-fluorouracil (other anticancer medicines);
Estonian: Docetaxel Mylanit kasutatakse koos tsisplatiini või 5-fluorouratsiiliga (samuti vähiravimid);
English: Docetaxel Mylan is a ‘generic medicine'.
Estonian: Docetaxel Mylan on geneeriline ravim.
English: • head and neck cancer in patients whose cancer is advanced (has started to spread).
Estonian: • pea- ja kaelapiirkonna kaugelearenenud (levima hakanud) vähk.
English: Docetaxel Mylan should be used in wards specialising in chemotherapy (medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.
Estonian: Ravi Docetaxel Mylaniga peab toimuma keemiaravile (vähi ravimravile) spetsialiseerunud osakonnas keemiaravipädevusega arsti järelevalve all.
English: Dexamethasone (an anti-inflammatory medicine) should also be given to the patient, starting on the day before the Docetaxel Mylan infusion.
Estonian: Enne Docetaxel Mylani infusiooni tuleb samal päeval anda patsiendile ka deksametasooni (põletikuravim).
English: Why has Docetaxel Mylan been approved?
Estonian: Miks Docetaxel Mylan heaks kiideti?
English: EPAR summary for the public docetaxel
Estonian: Kokkuvõte üldsusele dotsetakseel
English: How has Docetaxel Mylan been studied?
Estonian: Kuidas Docetaxel Mylanit uuriti?
English: How is Docetaxel Mylan used?
Estonian: Kuidas Docetaxel Mylanit kasutatakse?
English: How does Docetaxel Mylan work?
Estonian: Kuidas Docetaxel Mylan toimib?
English: What is Docetaxel Mylan used for?
Estonian: Milleks Docetaxel Mylanit kasutatakse?
English: What are the benefits and risks of Docetaxel Mylan?
Estonian: Milles seisneb Docetaxel Mylani kasulikkus ja mis riskid ravimiga kaasnevad?
English: It is used in adults and adolescents aged over 12 years and who weigh at least 35 kg.
Estonian: Seda kasutatakse täiskasvanutel ja üle 12-aastastel noorukitel, kes kaaluvad vähemalt 35 kg.
English: A risk management plan has been developed to ensure that Descovy is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Descovy võimalikult ohutu kasutamine.
English: The full EPAR for Descovy can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Descovy kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Descovy?
Estonian: Mis meetmed võetakse, et tagada Descovy ohutu ja efektiivne kasutamine?
English: Other information about Descovy
Estonian: Muu teave Descovy kohta
English: It does not cure HIV infection or AIDS, but it can hold off damage to the immune system and avoid the development of infections and diseases associated with AIDS.
Estonian: See ei ravi HIV-infektsiooni ega AIDSi välja, kuid võib immuunsüsteemi kahjustumist ning AIDSiga seotud nakkuste ja haiguste tekkimist edasi lükata.
English: Other common side effects include diarrhoea and headache.
Estonian: Teised sagedased kõrvalnähud on kõhulahtisus ja peavalu.
English: The company therefore presented data from the studies previously used to approve Genvoya, including 2 studies in 1,733 previously untreated adults, where around 90% of patients responded to treatment, and another study showing benefit was maintained when patients treated with other effective combinations were switched to Genvoya.
Estonian: Seetõttu esitas ettevõte andmed uuringutest, mida varem kasutati Genvoya heakskiitmiseks, sealhulgas kahest uuringust 1733 varem ravimata täiskasvanul, kellest ligikaudu 90%-l tekkis ravivastus, ja veel ühest uuringust, mis näitas, et kasulikkus säilis, kui teiste efektiivsete kombinatsioonidega ravitud patsiendid viidi üle ravile Genvoyaga.
English: The recommended dose is one tablet per day, and the strength of Descovy tablet chosen by the doctor depends on which other medicines it is given with.
Estonian: Soovitatav annus on üks tablett ööpäevas ja arsti poolt valitud Descovy tableti tugevus sõltub sellest, milliste teiste ravimitega koos seda manustatakse.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Descovy's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Descovy kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Why is Descovy approved?
Estonian: Miks Descovy heaks kiideti?
English: What is Descovy and what is it used for?
Estonian: Mis on Descovy ja milleks seda kasutatakse?
English: By blocking reverse transcriptase, Descovy reduces the amount of HIV in the blood and keeps it at a low level.
Estonian: Pöördtranskriptaasi blokeerimisega vähendab Descovy HIV-i kogust veres ja hoiab selle väikese.
English: What are the risks associated with Descovy?
Estonian: Mis riskid Descovyga kaasnevad?
English: The active substances in Descovy (emtricitabine and tenofovir alafenamide) are already approved to treat HIV infection together with two other active substances (elvitegravir and cobicistat) as part of the combination medicine Genvoya.
Estonian: Descovy toimeained (emtritsitabiin ja tenofoviiralafenamiid) on juba heaks kiidetud HIV-infektsiooni raviks koos kahe teise toimeainega (elvitegraviir ja kobitsistaat) osana kombinatsioonravimist Genvoya.
English: For the full list of all side effects and restrictions with Descovy, see the package leaflet.
Estonian: Descovy kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Descovy is available as tablets, each containing 200 mg of emtricitabine and either 10 or 25 mg of tenofovir alafenamide.
Estonian: Descovyt turustatakse tablettidena, mis sisaldavad 200 mg emtritsitabiini ja 10 või 25 mg tenofoviiralafenamiidi.
English: This is a summary of the European public assessment report (EPAR) for Descovy.
Estonian: See on ravimi Descovy Euroopa avaliku hindamisaruande kokkuvõte.
English: The most common side effect with Descovy (which may affect 1 in 10 people) is nausea (feeling sick).
Estonian: Descovy kõige sagedam kõrvalnäht (võib esineda 1 patsiendil 10-st) on iiveldus.
English: Descovy can only be obtained with a prescription and treatment should be started by a doctor experienced in managing HIV infection.
Estonian: Descovy on retseptiravim ja ravi peab alustama HIV-infektsiooni ravis kogenud arst.
English: It is not intended to provide practical advice on how to use Descovy.
Estonian: Hindamisaruandes ei anta Descovy kasutamise praktilisi nõuandeid.
English: Descovy emtricitabine / tenofovir alafenamide
Estonian: Descovy emtritsitabiin / tenofoviiralafenamiid
English: The company also provided data from supporting studies including studies looking at the way Descovy was absorbed in the body.
Estonian: Samuti esitas ettevõte toetavate uuringute, sealhulgas Descovy imendumist vaatlevate uuringute andmed.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Descovy, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Descovy omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For practical information about using Descovy, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Descovy kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: How does Descovy work?
Estonian: Kuidas Descovy toimib?
English: Descovy is an antiviral medicine used in combination with other medicines to treat individuals infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Descovy on viirusevastane ravim, mida koos teiste ravimitega kasutatakse omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava inimese I tüüpi immuunpuudulikkuse viiruse (HIV1) infektsiooni raviks.
English: Similarly to Genvoya, Descovy offers an alternative option to giving emtricitabine with tenofovir disoproxil
Estonian: Sarnaselt Genvoyale pakub Descovy alternatiivset võimalust lisaks emtritsitabiini manustamisele koos tenofoviirdisoproksiiliga.
English: Descovy contains tenofovir alafenamide which is effective at a lower dose than the established medicine tenofovir disoproxil and offers the possibility of reduced side effects.
Estonian: Descovy sisaldab tenofoviiralafenamiidi, mis on efektiivne väiksemas annuses kui hästi tõestatud meditsiinilise kasutusega ravim tenofoviirdisoproksiil ja millel on vähem kõrvalnähte.
English: For more information about treatment with Descovy, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Descovyga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Descovy contains the active substances emtricitabine and tenofovir alafenamide.
Estonian: Descovy sisaldab toimeainetena emtritsitabiini ja tenofoviiralafenamiidi.
English: These studies showed that Descovy produces comparable levels of emtricitabine and tenofovir alafenamide in the body to Genvoya.
Estonian: Need uuringud näitasid, et Descovy tekitab organismis Genvoyaga võrreldava emtritsitabiini ja tenofoviiralafenamiidi sisalduse.
English: How is Descovy used?
Estonian: Kuidas Descovyt kasutatakse?
English: What benefits of Descovy have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Descovy kasulikkus?
English: Tenofovir and emtricitabine are related antiviral agents called reverse transcriptase inhibitors.
Estonian: Tenofoviir ja emtritsitabiin on sarnased viirusevastased ained (pöördtranskriptaasi inhibiitorid), mis
English: They block the activity of reverse transcriptase, an enzyme made by the virus that allows it to reproduce itself in the cells it has infected.
Estonian: Pöördtranskriptaas on viiruse ensüüm, mis võimaldab HIV1-l nakatunud rakkudes paljuneda.
English: This summary was last updated in 04-2016.
Estonian: Descovy EMA/169100/2016
English: It can only be used in patients who weigh more than 47 kg.
Estonian: Ravimit saab kasutada ainult patsientidel, kes kaaluvad vähemalt 47 kg.
English: This summary was last updated in 02-2010.
Estonian: Kokkuvõtte viimane uuendus: 02-2010.
English: This includes adults (aged 18 years and older) who are also infected with human immunodeficiency virus (HIV).
Estonian: Sealhulgas ka vähemalt 18-aastased täiskasvanud patsiendid, kellel on inimese immuunpuudulikkuse viiruse (HIV) nakkus.
English: It is available as round,
Estonian: Seda turustatakse ümmarguste
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ribavirin BioPartners to BioPartners GmbH on 6 April 2010.
Estonian: Euroopa Komisjon andis ravimi Ribavirin BioPartners müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele BioPartners GmbH 6. aprillil 2010.
English: Ribavirin BioPartners is taken with food each day in two divided doses (morning and evening).
Estonian: Ravimit Ribavirin BioPartners manustatakse iga päev koos toiduga, jagades annuse kahte ossa (hommikul ja õhtul).
English: Ribavirin BioPartners can also be used in adults whose disease has come back after previous treatment or whose previous treatment
Estonian: Ravimit Ribavirin BioPartners võib kasutada ka täiskasvanud patsientidel, kelle haigus on pärast eelmist ravi taastunud või kellele varasem ravi ei ole
English: Ribavirin BioPartners must never be used on its own but only together with peginterferon alfa 2b or interferon alfa 2b (other medicines used in
Estonian: Ravimit Ribavirin BioPartners ei tohi kunagi kasutada ainsa ravimina, vaid ainult koos alfa-2b-peginterferooniga või alfa2b-interferooniga (samuti hepatiidiravimid).
English: Therefore, the CHMP's view was that, as for Rebetol, the benefit outweighs the identified risk.
Estonian: Sel põhjusel arvas inimravimite komitee, et nagu ka Rebetoli korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ribavirin BioPartners.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit Ribavirin BioPartners, et toetada ravimi müügiloa andmist ja koostada ravimi kasutamistingimuste soovitused.
English: Ribavirin BioPartners is thought to interfere with the production or action of viral DNA and RNA, which are needed for viruses to survive and multiply.
Estonian: Arvatakse, et Ribavirin BioPartners häirib viiruste püsimiseks ja paljunemiseks vajaliku viiruse-DNA jaRNA teket või toimet.
English: Because Ribavirin BioPartners is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.
Estonian: Et Ribavirin BioPartners on geneeriline ravim ja bioekvivalentne võrdlusravimitega, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimitel.
English: This means that Ribavirin BioPartners is similar to a ‘reference medicine' already authorised in the European Union (EU) called Rebetol.
Estonian: See tähendab, et Ribavirin BioPartners on sarnane võrdlusravimiga Rebetol, millel juba on Euroopa Liidus müügiluba.
English: The Committee recommended that Ribavirin BioPartners be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi Ribavirin BioPartners müügiloa.
English: The CHMP concluded that, in accordance with EU requirements, Ribavirin BioPartners has been shown to have comparable quality and to be bioequivalent to Rebetol.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Ribavirin BioPartners võrdväärne kvaliteet ja bioekvivalentsus ravimiga Rebetol.
English: This document is a summary of the European Public Assessment Report (EPAR) for Ribavirin BioPartners.
Estonian: Käesolev dokument on ravimi Ribavirin BioPartners Euroopa avaliku hindamisaruande kokkuvõte.
English: Ribavirin BioPartners on its own has no effect on eliminating the hepatitis C virus from the body.
Estonian: Ribavirin BioPartners ainsa ravimina ei mõjuta C-hepatiidi viiruse kõrvaldamist
English: Ribavirin BioPartners is a medicine that contains the active substance ribavirin.
Estonian: Ribavirin BioPartners on ravim, mis sisaldab toimeainena ribaviriini.
English: Because Ribavirin BioPartners is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Rebetol.
Estonian: Et Ribavirin BioPartners on geneeriline ravim, piirdusid uuringud katsetega, milles näidati ravimi Ribavirin BioPartners bioekvivalentsust võrdlusravimiga Rebetol.
English: Ribavirin BioPartners is used to treat long-term hepatitis C (a disease of the liver due to infection with the hepatitis C virus) in patients aged three years and older.
Estonian: Ravimit Ribavirin BioPartners kasutatakse kroonilise (pikaajalise) C-hepatiidi (C-hepatiidi viiruse nakkusest põhjustatud maksahaigus) raviks vähemalt 3-aastastel patsientidel.
English: Other information about Ribavirin BioPartners:
Estonian: Muu teave ravimi Ribavirin BioPartners kohta
English: Ribavirin BioPartners is a ‘generic medicine'.
Estonian: Ribavirin BioPartners on geneeriline ravim.
English: Why has Ribavirin BioPartners been approved?
Estonian: Miks Ribavirin BioPartners heaks kiideti?
English: For more information about treatment with Ribavirin BioPartners, read the Package Leaflet (also part of the EPAR).
Estonian: Üksikasjalik teave ravimiga Ribavirin BioPartners ravi kohta on pakendi infolehel, mis on samuti Euroopa avaliku
English: The active substance in Ribavirin BioPartners, ribavirin, is an antiviral belonging to the class ‘nucleoside analogues'.
Estonian: Ravimi Ribavirin BioPartners toimeaine ribaviriin on nukleosiidianaloogide klassi kuuluv viiruseravim.
English: Treatment with Ribavirin BioPartners should be started and monitored by a doctor who has experience in the management of long-term hepatitis C. The dose of Ribavirin BioPartners is based on the patient's body weight, and ranges from three to seven tablets a day.
Estonian: Ravimi Ribavirin BioPartners annus põhineb patsiendi kehakaalul ja on 3-7 tabletti päevas.
English: How has Ribavirin BioPartners been studied?
Estonian: Kuidas ravimit Ribavirin BioPartners uuriti?
English: The full EPAR for Ribavirin BioPartners can be found here.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Ribavirin BioPartners kohta on siin.
English: Ribavirin BioPartners is used in patients who have not been treated before, as long as the liver is still working and hepatitis C virus can be found in the blood.
Estonian: Ravimit Ribavirin BioPartners kasutatakse varem ravimata C-hepatiidiga patsientide raviks, kelle maks veel toimib.
English: How is Ribavirin BioPartners used?
Estonian: Kuidas ravimit Ribavirin BioPartners kasutatakse?
English: What is Ribavirin BioPartners used for?
Estonian: Milleks ravimit Ribavirin BioPartners kasutatakse?
English: What are the benefit and risk of Ribavirin BioPartners?
Estonian: Milles seisneb ravimi Ribavirin BioPartners kasulikkus ja mis riskid
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ipreziv on 07 December 2011.
Estonian: Euroopa Komisjon andis Iprezivi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 7. detsembril
English: The full EPAR for Ipreziv can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Iprezivi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It is available as tablets (20 mg, 40 and 80 mg).
Estonian: Seda turustatakse tablettidena (20 mg, 40 mg ja 80 mg).
English: Other information about Ipreziv
Estonian: Muu teave Iprezivi kohta
English: The studies lasted between six and 56 weeks and the main measure of effectiveness was the change in the systolic blood pressure (blood pressure when the heart is contracting).
Estonian: Uuringud kestsid kuus kuni 56 nädalat ja efektiivsuse põhinäitaja oli süstoolse vererõhu (vererõhk südame kokkutõmbumise ajal) muutus.
English: Eight main studies involving over 6,000 patients with essential hypertension were carried out with Ipreziv.
Estonian: Ipreziviga tehti kaheksa põhiuuringut, kus osales rohkem kui 6000 essentsiaalse hüpertensiooniga patsienti.
English: What is Ipreziv?
Estonian: Mis on Ipreziv?
English: Ipreziv is taken by mouth and the usual recommended dose is 40 mg once a day.
Estonian: Iprezivi võetakse suu kaudu ja tavaline soovitatav annus on 40 mg üks kord ööpäevas.
English: Ipreziv 40 and 80 mg was also more effective than ramipril (10 mg).
Estonian: Annustes 40 ja 80 mg oli Ipreziv ka ramipriilist (10 mg) efektiivsem.
English: Side effects with Ipreziv are generally mild or moderate, with the most common side effect being dizziness.
Estonian: Iprezivi kõrvalnähud on üldiselt kerged või mõõdukad, kõige sagedam kõrvalnäht on peapööritus.
English: The studies also showed that Ipreziv, when taken in combination with other medicines, can produce additional decreases in blood pressure compared with when these medicines are taken without Ipreziv.
Estonian: Uuringud näitasid ka, et koos teiste ravimitega võetuna võib Ipreziv suurendada vererõhu langust, võrreldes nende ravimite võtmisega ilma Iprezivita.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ipreziv.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: This is a summary of the European public assessment report (EPAR) for Ipreziv.
Estonian: See on ravimi Ipreziv Euroopa avaliku hindamisaruande kokkuvõte.
English: The Committee decided that the benefits of Ipreziv are greater than its risks in patients with essential hypertension and recommended that it be given marketing authorisation.
Estonian: Komitee otsustas, et Iprezivi kasulikkus essentsiaalse hüpertensiooniga patsientidel on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Ipreziv on its own was more effective than placebo.
Estonian: Ipreziv oli ainuravimina efektiivsem kui platseebo.
English: In the two studies with Ipreziv taken alone compared with placebo, patients had an average fall in systolic blood pressure of about 13.5 mmHg on Ipreziv 40 mg and a fall of about 14.5 mmHg on Ipreziv 80 mg after 6 weeks.
Estonian: Kahes uuringus, kus ainuravimina võetavat Iprezivit võrreldi platseeboga, langes 40 mg Iprezivit võtnud patsientide süstoolne vererõhk kuue nädala pärast keskmiselt 13,5 mm Hg ja 80 mg Iprezivit võtnud patsientidel umbes 14,5 mm Hg.